Exosome Liquid Biopsy Platform ExoDetect Receives FDA Approval: Single Blood Draw Screens for 8 Early-Stage Cancers
Guardant Health's exosome liquid biopsy platform ExoDetect receives FDA approval, detecting tumor-derived exosome protein and RNA biomarkers in blood for early screening of 8 cancer types from a single 10mL blood draw.
Exosome Liquid Biopsy Platform ExoDetect Receives FDA Approval: Single Blood Draw Screens for 8 Early-Stage Cancers
US liquid biopsy company Guardant Health announced on December 25 that its exosome liquid biopsy platform ExoDetect has received FDA approval. This is the first multi-cancer early screening product based on exosome detection technology, requiring just 10mL of blood to screen for lung, colorectal, pancreatic, liver, ovarian, gastric, esophageal, and bladder cancers.
Exosomes are nanoscale vesicles secreted by cells, 30-150 nanometers in diameter. Tumor cells release large quantities of exosomes carrying tumor-specific proteins and RNA into the bloodstream. Compared to circulating tumor DNA detection, exosome detection offers 100x higher signal abundance from early-stage tumors.
ExoDetect combines high-throughput exosome isolation, mass spectrometry proteomics, and RNA sequencing, detecting 127 protein biomarkers and 204 RNA biomarkers simultaneously, with machine learning models determining cancer signal presence and tissue of origin.
In an 18,000-subject clinical trial, ExoDetect achieved 73.2% sensitivity for Stage I cancers overall with 98.5% specificity. Stage I pancreatic cancer sensitivity reached 68.4%, far exceeding any existing screening method. Single-test pricing is $950, with insurance coverage negotiations underway.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.